Sun Can't Sell Generic Eloxatin Until 2012: Judge

Law360, New York (September 16, 2011, 9:08 PM EDT) -- Sun Pharmaceutical Industries Ltd. can't market its generic version of Sanofi-Aventis SA's colorectal cancer treatment Eloxatin until August 2012, based on the terms of a licensing agreement between the companies, a New Jersey federal judge said Thursday.

U.S. District Court Judge Joel A. Pisano reinstated his April 22, 2010, judgment entering a consent decree that resolved Sanofi's patent infringement suit against Sun. The decree includes licensing language stating that if other generics makers were enjoined from selling their version of Eloxatin at-risk, Sun would be enjoined...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.